A Phase 2 open-label study was conducted on 46 previously untreated patients with high-risk DLBCL to evaluate durvalumab, a high-affinity human IgG1 monoclonal antibody that selectively blocks PD-L1 binding to PD-1 and CD80. Here, PDCD1 is linked to diffuse large B-cell lymphoma.